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REVIEW
Abstract: Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-
adrenergic receptors than other agents in this class and a nitric oxide (NO)-potentiating,
vasodilatory effect that is unique among beta-blockers currently available to clinicians
(nebivolol is approved in Europe and is currently under review in the US). A NO-potentiating
agent such as nebivolol may have an important role in hypertensive populations with reduced
endothelial function such as diabetics, African-Americans and those with vascular disease.
Nebivolol is a racemic mixture with beta-blocker activity residing in the d-isomer; in contrast,
l-nebivolol is far more potent in facilitating NO release. Nebivolol is unique among beta-
blockers in that, at doses <10 mg, it does not inhibit the increase in heart rate normally seen
with exercise. The efficacy of nebivolol has been tested successfully in clinical trials against
other agents including other beta-blockers, angiotensin-converting enzyme-inhibitors and
calcium channel antagonists in patients with hypertension, angina, and congestive heart failure.
The tolerability of nebivolol has been shown to be superior to that of atenolol and metoprolol.
In controlled clinical trials, nebivolol has a side effect profile that is similar to placebo, in
particular as it relates to fatigue and sexual dysfunction. This article will review published
clinical data regarding this cardioselective beta-blocker.
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Introduction
Goal blood pressure (BP), defined as <140/90 mm Hg in uncomplicated hypertension,
is attained by only 34% of hypertensive patients in the US (Chobanian et al 2003),
24% of patients in France (Chamontin et al 1998), and 13% of patients in Canada
(Joffres et al 2001). These low rates of achieving goal BP indicate that a more
aggressive approach to BP management is required on a global scale. One of the
most important classes of antihypertensive agents, beta-blockers play a critical role
in reducing cardiovascular risk in hypertensive patients. A meta-analysis including
almost 19 000 patients concluded that beta-blocker therapy was associated with a
42% reduction in heart failure, a 29% reduction in stroke risk, and a 7% reduction in
coronary heart disease in hypertensive patients (Psaty et al 1997). The specific
mechanism of action of beta-blockers that reduces BP is not completely understood,
however, likely mechanisms include an effect on heart rate, inhibition of the
sympathetic nervous system, and inhibition of the renin-angiotensin system. Nebivolol
is a novel, highly selective beta-blocker with nonadrenergic vasodilating properties.
It has been approved for the treatment of essential hypertension and congestive heart
failure in Europe and is currently under review for the treatment of hypertension in
the US.
Pharmacokinetics
Nebivolol is a racemic mixture of equal proportions of d- and l-isomers. The beta-
blocker activity resides in the d-isomer while the facilitation of nitric oxide (NO)
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release is found in the l-enantiomer (Van Neuten and De
Cree 1998; Mason et al 2005).
Nebivolol is well absorbed after oral administration.
Peak plasma concentrations are reached in 0.5–2 hours and
steady-state plasma levels are reached in 24 hours (McNeely
and Goa 1999). Nebivolol has a superior trough-to-peak
efficacy ratio compared with atenolol, allowing for “true”
once daily dosing (Simon and Johnson 1993). Absorption
of the drug following oral administration is not affected by
food, age, gender or body weight (McNeely and Goa 1999;
Cheymol et al 1997). Nebivolol is metabolized by the liver,
and undergoes extensive first-pass metabolism to active
moieties via the cytochrome (CYP)2D6 enzymatic pathway
(Gu et al 2003; Weber 2005). The mean terminal half-life is
approximately 10 hours (Cheymol et al 1997). Less than
0.1% of unchanged drug is excreted in urine (Shaw, Liu,
Zachwieja, et al 2005). Metabolism of nebivolol is subject
to a debrisoquine-type genetic polymorphism (Weber 2005).
The small percentage of patients who are deficient in CYP2D6
enzyme activity (7% of Caucasians, 2% of African-Americans,
2% of Asians) are considered poor metabolizers of nebivolol
(Relling et al 1991; Evans et al 1993; Mizutani 2003). The
absolute oral bioavailability of nebivolol is 12% in extensive
metabolizers and 96% in poor metabolizers (Van Peer 1991).
However, a safety trial in both extensive and poor metabolizers
has shown no safety or efficacy differences between these
patient groups (Lacourcière et al 2000).
No significant difference in efficacy or safety have been
found in patients with mild or moderate renal disease;
patients with severe renal impairment may need a lower
initial dose due to impaired clearance (Shaw, Liu, Zachwieja,
et al 2005). Similarly, a lower starting dose may be needed
in patients with mild or moderate hepatic impairment due
to alteration in the drug’s pharmacokinetics in these patients
(Shaw, Liu, Tu, et al 2005).
Clinical perspective
Nebivolol has a hemodynamic effect suggestive of direct
vasodilatation (Gao et al 1991; Van Rooy et al 1991).
Evidence in the literature indicates that the vasodilation
associated with nebivolol is due to its effects on the L-
arginine/NO pathway in the endothelium of various regional
vascular beds (Bowman et al 1994; Cockcroft et al 1995;
Dawes et al 1999; Ritter 2001; Tzemos et al 2001). Using
the dorsal hand vein dilatation model, researchers found
that nebivolol had a venodilator effect on the human hand
whereas atenolol did not. Further, this effect was inhibited
by L-NMMA (NG-monomethyl L-arginine), an inhibitor of
NO synthase, indicating that the increased blood flow was
due to activation of the L-arginine/NO pathway (Bowman
et al 1994). This finding was confirmed in hypertensive
patients who showed signs of vasodilatation in forearm
arteries after nebivolol infusion. The fact that this
vasodilatation was inhibited by L-NMMA supports that it
is due to activation of the L-arginine/NO pathway (Cockcroft
et al 1995; Dawes et al 1999). The endothelial-dependent
vasoconstrictive response seen with L-NMMA infusion was
inhibited by nebivolol and not by atenolol (Ritter 2001;
Tzemos et al 2001).
In another study, the effect of nebivolol on small artery
distensibility in patients with hypertension was compared
with that of atenolol. Both drugs were equivalent in reducing
BP, but only nebivolol improved small artery distensibility,
a measure of arterial compliance or “stiffness” (Arosio et al
2002). Arterial stiffness has been shown to be an
independent predictor of mortality in patients with essential
hypertension. Drugs that reduce stiffness may therefore
confer a survival advantage (Laurent et al 2001). In an
animal model comparison with atenolol, nebivolol infusion
showed a statistically significant reduction in a measure of
arterial distensibility, namely pulse wave velocity, with no
change in mean arterial pressure (McEniery et al 2004). In
contrast, atenolol had no effect on pulse wave velocity
despite a small drop in mean arterial pressure. This difference
suggests that the release of NO mediated by nebivolol,
independent of a beta-adrenoceptor-dependent mechanism,
an effect not seen with older beta-blockers such as atenolol,
may be of particular benefit in patients with impaired arterial
compliance, such as those with isolated systolic hypertension
(McEniery et al 2004).
Clinical trials also show that nebivolol has an anti-
oxidative effect (de Groot et al 2004; Pasini et al 2005). In
a study of 20 hypertensive patients compared with 20
matched healthy subjects, nebivolol reduced the oxidative
inactivation of NO, a result not seen with atenolol (Pasini
et al 2005). In addition, nebivolol inhibited vascular smooth
muscle proliferation in a rat aortic smooth muscle cell model
via an apparent NO-dependent mechanism (Ignarro et al
2002). Both of these findings suggest that nebivolol may
offer anti-atherosclerotic activity, a particular benefit, if
verified, in patients with arterial disease.
Nebivolol comparative efficacy
Clinical trials suggest that on a weight-for-weight basis,
nebivolol is ten times more potent than atenolol. In one study,
the effect of doses of nebivolol (2.5 mg/day, 5.0 mg/day, andVascular Health and Risk Management 2006:2(3) 305
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10.0 mg/day) on exercise-induced increases in heart rate and
blood pressure in 25 male hypertensive volunteers was
compared with that of atenolol 50 mg/day and 100 mg/day
and of placebo using a double-blind, crossover design and
a parallel, placebo group (n=7) (Simon and Johnson 1993).
At 24 hours after dosing, sitting and standing diastolic and
systolic blood pressures and heart rates (at rest and during
submaximal exercise) were reduced to the same extent by
nebivolol and atenolol.
However, the hemodynamic effect of nebivolol appears
to be different from that of atenolol. In a double-blind,
randomized, prospective study in patients with essential
hypertension, atenolol reduced cardiac output, stroke
volume, and heart rate. In contrast, nebivolol reduced
peripheral resistance and increased stroke volume,
preserving cardiac output (Kamp et al 2003). The effects of
nebivolol demonstrated in this study suggest that the drug
may be important in treating heart failure, where
preservation of cardiac output is critical.
Nebivolol 5 mg/day was compared with metoprolol
100 mg twice daily (BID) in 155 patients with mild-to-
moderate essential hypertension (Uhlir et al 1991). Target
blood pressure was attained in 79% of nebivolol-treated
patients and 66% of those in the metoprolol group. There
were fewer adverse events reported by patients in the
nebivolol group. In a second study, nebivolol 5 mg/day was
compared with metoprolol 100 mg BID in 80 newly
diagnosed hypertensive patients (Celik et al 2006). After 6
months of treatment, the researchers found that both drugs
significantly reduced BP and heart rate, with a more
profound bradycardic effect seen in the metoprolol group.
In contrast, only nebivolol significantly reduced oxidative
stress, insulin resistance index, and plasma levels of P-
selectin, a cell-surface adhesion molecule believed to play
a role in the initiation of atherosclerosis (Celik et al 2006).
Nebivolol 5 mg/day was also compared with the
angiotensin-converting enzyme (ACE) inhibitor lisinopril
20 mg/day in 68 patients with uncomplicated mild-to-
moderate hypertension, treated for 12 weeks. The primary
endpoints of the study were response rate, where patients
were defined as “normalized” responders if their blood
pressure values were <140/90 mm Hg at study end, or as
“non-normalized” responders if the reduction in blood
pressure was ≥10 mm Hg compared with baseline; and
changes in sitting blood pressure at the end of the study.
Patients were randomly assigned to one of the study arms,
however, a significant difference in sitting diastolic blood
pressure (DBP) was found between the 2 groups at baseline.
Analysis of covariance of the raw data including baseline
values as covariate suggested that DBP and heart rate were
significantly lower in the nebivolol-treated group at week
8. This difference disappeared, however, when an analysis
of variance for repeated measures was performed, which
indicated a significant reduction in systolic blood pressure
(SBP), DBP, and heart rate in both groups. There was a
statistically significant difference in favor of the nebivolol
group in the distribution of responders and non-responders
at week 8. Lisinopril and nebivolol were equally well
tolerated (Rosei et al 2003).
Nebivolol 2.5–5 mg/day was compared with the calcium
channel antagonist, amlopidine, 5–10 mg/day (Mazza et al
2002) in elderly patients (≥65 years). In this double-blind,
multicenter, randomized trial, efficacy was similar between
the two groups. Both drugs were well tolerated, however,
there was a higher incidence of adverse events such as
headache and ankle edema in the group treated with
amlodipine. In a double-blind study, the efficacy of nebivolol
5 mg/day was compared with that of the sustained-release
calcium channel antagonist, nifedipine, 20 mg/BID in 51
patients with mild-to-moderate hypertension over a 12 week-
treatment period (Lacourcière et al 1992). The treatment
response rate was 69% for nebivolol and 59% for nifedipine.
Both treatment groups showed a significant reduction in
BP, with no significant difference in BP reduction between
the groups either in clinic BP or in 24-hour ambulatory BP.
Nebivolol appeared to be superior to nifedipine in preventing
the usual early morning increase in BP. Beta-blockers have
usually been found to increase plasma cholesterol (Ames
1986; Lacourcière et al 1990). However, both agents were
associated with a significant decrease in cholesterol after
12 weeks of treatment, 5% and 3%, for nebivolol and
nifedipine, respectively.
The largest double-blind study in hypertension included
909 patients with mild-to-moderate hypertension (Weiss et
al 2005). Nebivolol in doses of 1.25–40 mg/day were
compared with placebo over 12 weeks. Placebo-subtracted
reductions in trough sitting BP (SBP/DBP) ranged from 6.6/
5.1–11.7/8.3 mm Hg and were dose dependent. Reported
adverse events were: headache (7.1 vs 7.4% placebo, fatigue
(3.6 vs 2.5% placebo, nasopharyngitis (2.9% vs 7.4%
placebo), diarrhea (2.8% vs 2.5% placebo) and dizziness
(2.8 vs 3.7% placebo). The incidence of typical beta-blocker
adverse effects was very low and no different from placebo
including erectile dysfunction (0.2% vs 0.0% placebo),
decreased libido (0.1% vs 0.0% placebo), dyspnea (1.0%
vs 0.0% placebo) and bradycardia (0.7% vs 0.0% placebo).Vascular Health and Risk Management 2006:2(3) 306
Weiss
Nebivolol tolerability
In controlled clinical trials, nebivolol demonstrates a side
effect profile similar to placebo, most notably in regards to
side effects commonly associated with beta-blockers, such
as fatigue and sexual dysfunction (Weber 2005). Quality of
life was evaluated in a double-blind, randomized trial of
314 patients with hypertension who were treated with either
nebivolol 5 mg/day or losartan 50 mg/day for 12 weeks (Van
Bortel et al 2005). The two agents had an equivalent effect
in reducing SBP but the decrease in DBP was slightly greater
with nebivolol. Interestingly, the side effect profile of
losartan, an angiotensin receptor antagonist known for few
side effects, was no different than that of nebivolol. In a
separate study, nebivolol (5 mg/day) was compared with
atenolol (50 mg/day) and placebo in 364 patients in general
practice (Van Nueten et al 1998). There was no significant
difference in BP or in sitting heart rate between the treatment
groups, and there was no significant difference in the
incidence of side effects between the groups, except for
significantly more complaints of sexual dysfunction in the
atenolol group.
Beta-blockers have been associated in the past with a
risk of sexual dysfunction, however recent meta-analysis
suggests that the risk of this adverse event is not substantial
(Ko et al 2002). A recent clinical trial studied 29 out of 44
hypertensive men who complained of erectile dysfunction
while taking atenolol, metoprolol or bisoprolol. The
researchers found that after switching to nebivolol therapy,
20 of the 29 noted significant improvement in erectile
function without a significant change in BP (Doumas et al
2006). It is reasonable to speculate that this improvement
in erectile function may be due to the involvement of NO in
erectile dysfunction and its potentiation with nebivolol
therapy (Doumas et al 2006).
Nebivolol in other cardiovascular
diseases
Nebivolol (5 mg/day) versus placebo has been evaluated in
the treatment of angina (Cherchi et al 1991). In a placebo-
controlled trial of 16 patients, nebivolol therapy significantly
prolonged treadmill time to 1 mm ST depression from 555
± 37sec to 667.5 ± 49 sec (p<0.05). Anginal threshold was
also significantly delayed from 697 ± 51 sec to 767 ± 64 sec
(p<0.05). Further testing of nebivolol in a dose ranging,
single-blind trial (2.5 mg/day, 5 mg/day, and 10 mg/day) was
performed in 10 patients with stable angina; 5 of the patients
also had a history of myocardial infarction (Ulvenstam
1991). The doses were titrated in 2 week intervals in this
trial. The time to 1 mm ST change increased at all 3 doses
of nebivolol compared with placebo.
In a double-blind, placebo-controlled study of maximal
and submaximal exercise testing conducted in patients with
ischemic left ventricular dysfunction but no overt signs of
heart failure, both atenolol and propanolol reduced resting
heart rate and improved left ventricular ejection fraction
compared with placebo. Only nebivolol produced a parallel,
downward shift of the pressure-volume relationship during
early diastolic filling and improved the early peak filling
rate compared with placebo (Rousseau et al 1996). In
addition, compared with baseline, nebivolol therapy
increased maximal exercise duration by 44 sec, a statistically
significant difference from baseline (p=0.007 vs baseline),
whereas the improvements seen with placebo and atenolol,
7 sec and 13 sec respectively, were not statistically significant
changes from baseline.
In patients with ischemic left ventricular dysfunction
without clinical congestive heart failure (Stoleru et al 1993),
maximal exercise function increased more in those treated
with nebivolol 5 mg/day than in those treated with atenolol
50 mg/day (p<0.0077). This was associated with an
improved pressure-volume relationship during early
diastolic filling and improved early peak filling rate. An
improvement in left ventricular ejection fraction and cardiac
output was found with nebivolol, but not with atenolol.
The Study of the Effects of Nebivolol Intervention on
Outcomes and Rehospitalisation in Seniors with Heart
Failure (SENIORS) was a double-blind, randomized,
multicenter placebo-controlled trial conducted in Europe.
SENIORS was the first randomized, controlled clinical trial
with the power to demonstrate efficacy specifically in elderly
patients with heart failure. The aim of the study was to assess
the effect of nebivolol on mortality and cardiovascular
hospital admissions in elderly patients (≥70 years) with heart
failure, regardless of ejection fraction (Flather et al 2005).
The SENIORS researchers note that this age inclusion
criterion makes the study population closely resemble the
actual population of heart failure patients, where the average
age is 76 years; in contrast, the average age of patients
enrolled in previous, large heart failure studies was 63 years.
All 2128 patients enrolled in the SENIORS study had a
history of chronic heart failure, as evidenced by hospital
admission within the past 12 months with a diagnosis of
congestive heart failure on discharge or a documented
ejection fraction of 35% or less within the previous 6
months. Following randomization, 1067 patients receivedVascular Health and Risk Management 2006:2(3) 307
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nebivolol 1.25 mg/day titrated to 10 mg/day; 1061 patients
received placebo. The primary outcome of the study was a
composite of all-cause mortality or cardiac hospitalization
(time to first event) during a 21 month follow up period. At
baseline, the mean ejection fraction was 36%, with 35% of
patients having an ejection fraction >35%. More than two
thirds of patients (68%) had a history of coronary artery
disease. The primary outcome occurred in 31.1% (n=332)
of nebivolol-treated patients and 35.3% (n=375) of patients
receiving placebo (hazard ratio [HR] 0.86; 95% confidence
interval [CI]: 0.74–0.99; p=0.039). The all-cause mortality
rate was 15.8% (n=169) in the nebivolol group and 18.1%
(n=192) in the placebo group (HR 0.88, 95% CI 0.71–1.08;
p=0.21) Subgroup analysis by age less than the median age
in SENIORS (75.2 years) in patients with an ejection fraction
less than 35% allowed comparison with the results of
previous trials; the HR for primary outcome was 0.73 (95%
CI, 0.56–0.96), the HR for all cause mortality alone was
0.62 (95% CI, 0.43–0.89). These results suggest that the
efficacy of nebivolol in this patient subgroup is similar to
that seen in previous studies conducted with bisoprolol,
metoprolol, and carvedilol (Flather et al 2005).
Nebivolol efficacy in black
hypertensive patients
The efficacy and tolerability of nebivolol in black
hypertensive patients was assessed in a randomized,
placebo-controlled, multicenter trial conducted in Europe
and the US that included 509 patients with essential
hypertension (Van Neuten et al 1997). Doses of 0.5 mg/day,
1.0 mg/day, 2.5 mg/day, 5 mg/day and 10 mg/day of
nebivolol were compared with placebo. Doses of nebivolol
at 2.5 mg/day, 5 mg/day, and 10 mg/day were shown to be
more effective than placebo in a dose-dependent manner.
There was no significant difference in efficacy seen between
black (22% of the study population) and white patients, with
response rates of 58% and 62%, respectively (response
defined as reduction of DBP to <90 mm Hg or by ≥10 mm
Hg from baseline). The drug was well tolerated.
The efficacy of nebivolol in black patients may in part
be due to improved NO levels. The importance of NO in
black patients has been shown in the treatment of congestive
heart failure where a regimen of hydralazine and nitrates
reduced mortality by 43% over a standard regimen including
an ACE inhibitor and a beta-blocker (Taylor et al 2004).
Nebivolol has been shown to restore NO bioavailability in
blacks to the level observed in whites, independent of beta1-
selective blockade, by augmenting NO release and reducing
nitroxidative stress in the vascular endothelium (Mason et
al 2005). These findings suggest that nebivolol may be a
more effective antihypertensive in black patients than older
beta-blockers.
Conclusions
Beta-blockers are important agents in cardiovascular
medicine, proving critically important in the management
of hypertension and heart failure and in reducing
cardiovascular risk. Nebivolol is a novel highly
cardioselective beta-blocker with antihypertensive efficacy
similar to that of other beta-blockers, but with tolerability
better than older agents in its class, which may permit
nebivolol to be used more widely and effectively than other
beta-blockers. Nebivolol’s vasodilating effect, its anti-
atherosclerotic effect, and its positive effects on arterial
compliance suggest that it may provide more cardiovascular
benefits than traditional beta-blockers, particularly in
patients with isolated systolic hypertension, diabetics, black
patients, and patients with known vascular disease.
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